Expression of Tenascin-C in intraductal carcinoma of human breast: Relationship to invasion

European Journal of Cancer

Volumn 34, Issue 11, 1998, Pages 1687-1692

  Jahkola, T ^a   Toivonen, T ^b   Nordling, S ^c   Von Smitten, K ^a   Virtanen, I ^d  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b KYMENLAAKSO CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Breast cancer; Intraductal carcinoma; Invasion; Tenascin

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TENASCIN;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER INVASION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL DIVISION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TENASCIN;

EID: 0032189621     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00215-9     Document Type: Article

References (33)

1. 1. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. Review. N Engl J Med 1986, 315(26), 1650-1659.
2. 2. Birchmeier C, Birchmeier W. Molecular aspects of mesenchymal-epithelial interactions. Ann Rev Cell Biol 1993, 9, 511-540.
3. 3. Vollmer G. Biologic and oncologic implications of tenascin-C/ hexabrachion proteins. Crit Rev Oncol/Hematol 1997, 25, 187-210.
4. 4. Lightner VA, Marks JR, McCachren SS. Epithelial cells are an important source of tenascin in normal and malignant human breast tissue. Exp Cell Res 1994, 210(2), 177-184.
5. 5. Yoshida T, Matsumoto E-I, Hanamura N, et al. Co-expression of tenascin and fibronectin in epithelial and stromal cells of benign lesions and ductal carcinomas in the human breast. J Pathol 1997, 182, 421-428.
6. 6. Howeedy AA, Virtanen I, Laitinen L, Gould NS, Koukoulis GK, Gould VE. Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Lab Invest 1990, 63(6), 798-806.
7. 7. Shoji T, Kamiya T, Tsubura A, et al. Immunohistochemical staining patterns of tenascin in invasive breast carcinomas. Virchows Archiv A 1992, 421, 53-56.
8. 8. Moch H, Torhorst J, Durmuller U, Feichter GE, Sauter G, Gudat F. Comparative analysis of the expression of tenascin and established prognostic factors in human breast cancer. Pathol Res Practice 1993, 189, 510-514.
9. 9. Jahkola T, Toivonen T, Smitten K von, Blomqvist C, Virtanen I. Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer (Pred Oncol) 1996, 69, 445-447.
10. 10. Jahkola T, Toivonen T, Virtanen, I. et al., Tenascin-C expression in invasion border of early breast cancer - a predictor of local and distant recurrence. Br J Cancer (in press).
11. 11. Rosai J. Breast. In Rosai J, ed. Ackermann's Surgical Pathology, vol. 2, 8th edn. Mosby, St Louis, Toronto, 1996, 1596.
12. 12. Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989, 63, 618-624.
13. 13. Fisher ER, Costantino J, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). Cancer 1995, 75, 1310-1319.
14. 14. Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995, 345, 1154-1157.
15. 15. Blume E. News: New clinical trials under way for DCIS. J Natl Cancer Inst 1997, 89(15), 1094.
16. 16. Mackie EJ, Halfter W, Liverani D. Induction of tenascin in healing wounds. J Cell Biol 1988, 107, 2757-2767.
17. 17. Holland R, Hendriks JHCL, Verbeek ALM, Mravunac M, Stekhoven JHS. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet 1990, 335, 519-522.
18. 18. Tiitta O, Wahlström T, Paavonen J, et al. Enhanced tenascin expression in cervical and vulvar koilocytotic lesions. Am J Pathol 1992, 141(4), 907-913.
19. 19. Boguslawski K von. Immunohistochemical detection of progesterone receptors in paraffin sections. A novel method using microwave oven pretreatment. Apmis 1994, 102, 641-646.
20. 20. Railo M, Nordling S, Boguslawski K von, Leivonen M, Kyllönen L, Smitten K von. Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 1993, 68, 579-583.
21. 21. Railo M, Lundin J, Haglund C, Smitten K von, Boguslawski K von, Nordling S. Ki-67, p53, ER-receptors, ploidy and s-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol 1997, 36(4), 369-374.
22. 22. Chiquet-Ehrismann R, Mackie EJ, Pearson CA, Sakakura T. An extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 1986, 47, 131-139.
23. 23. Koch M, Wehrle-Haller B, Baumgartner S, Spring J, Brubacher D, Chiquet M. Epithelial synthesis of tenascin at tips of growing bronchi and graded accumulation in basement membrane and mesenchyme. Exp Cell Res 1991, 194, 297-300.
24. 24. Sakakura T, Ishihara A, Yatani R. Tenascin in mammary gland development: from embryogenesis to carcinogenesis. In Lippman ME, ed. Regulatory Mechanisms in Breast Cancer. Boston; Kluwer Academic, 1991, 383-400.
25. 25. Shoji T, Kamiya T, Tsubura A, et al. Tenascin staining positivity and the survival of patients with invasive breast carcinoma. J Surg Res 1993, 55, 295-297.
26. 26. Sugawara I, Hirakoshi J, Masunaga A, Itoyama S, Sakakura T. Reduced tenascin expression in colonic carcinoma with lymphogenous metastasis. Invasion Metastasis 1991, 11, 325-331.
27. 27. Riedl S, Faissner A, Schlag P, Herbay AV, Koretz K, Möller P. Altered content and distribution of tenascin in colitis, colon adenoma, and colorectal carcinoma. Gastroenterology 1992, 103, 400-406.
28. 28. Ibrahim SN, Lightner VA, Ventimiglia JB, et al. Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. Human Pathol 1993, 24, 982-989.
29. 29. Sasano H, Nagura H, Watanabe K, et al. Tenascin expression in normal and abnormal human endometrium. Modern Pathol 1993, 6(3), 323-326.
30. 30. Tiitta O, Wahlström T, Virtanen I, Gould VE. Tenascin in inflammatory conditions and neoplasma of the urinary bladder. Virchows Archiv B 1993, 63, 283-287.
31. 31. Soini Y, Pääkkö P, Virtanen I, Lehto V-P. Tenascin in salivary gland tumours. Virchows Archiv A 1992, 421, 217-222.
32. 32. Soini Y, Pääkkö P, Nuorva K, et al. Tenascin immunoreactivity in lung tumors. Am J Clin Pathol 1993, 100(2), 145-150.
33. 33. Tiitta O, Happonen RP, Virtanen I, Luomanen M. Distribution of tenascin in oral premalignant lesions and squamous cell carcinoma. J Oral Pathol Med 1994, 23, 446-450.